Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder: A Systematic Review and Exploratory Meta-Analysis
CNS Drugs, 08/20/2012
Evidence Based Medicine
De Hert M et al. – While preliminary data suggest the lowest weight gain potential with lurasidone and potentially relevant short–term metabolic effects for asenapine and iloperidone, data are still too sparse to comprehensively evaluate the metabolic safety of the newly approved SGAs. Therefore, there is a clear need for further controlled studies to evaluate whether these agents are less problematic regarding treatment–emergent weight gain and metabolic disturbances than other currently available antipsychotics.